Encompass Health Corporation (EHC) Market Cap

Encompass Health Corporation (EHC) has a market capitalization of $10.76B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Medical - Care Facilities
Employees: 28572
Exchange: New York Stock Exchange
Headquarters: Birmingham, AL, US
Website: https://www.encompasshealth.com

Loading company profile...

Expand full investment commentary ▼

📘 ENCOMPASS HEALTH CORP (EHC) — Investment Overview

🧩 Business Model Overview

Encompass Health Corporation (EHC) is a leading provider of post-acute healthcare services, with a focus on inpatient rehabilitation therapy. The company operates a network of inpatient rehabilitation hospitals and offers specialized rehabilitative care to patients recovering from conditions such as stroke, neurological disorders, trauma, orthopedic surgeries, and cardiac events. Encompass Health’s business model centers on delivering intensive, outcome-focused therapy programs through its owned and operated hospitals, in partnership with acute care hospitals, or via joint ventures. The company's services target the growing demand for high-quality rehabilitative care, facilitating patient recovery and reintegration into daily life.

💰 Revenue Streams & Monetisation Model

Encompass Health derives the majority of its revenues from its inpatient rehabilitation hospital segment. Core revenue streams include: - **Patient Care Revenue:** Generated from services provided to patients during inpatient rehabilitation stays, billed primarily to government payors such as Medicare and Medicaid, and to commercial insurers. - **Ancillary Services:** Includes outpatient therapy, home-based care, and other outpatient services offered in select markets, though these are a smaller proportion of total revenues. - **Management and Consulting Fees:** EHC also earns fees from managing rehabilitation facilities in partnership or via joint ventures, leveraging its operational expertise. The monetisation model focuses on reimbursement for patient episodes based on established diagnosis-related group (DRG) codes, which influence the total payment per patient stay. Revenue predictability is influenced by patient mix, length of stay, acuity levels, and reimbursement rates negotiated with payors.

🧠 Competitive Advantages & Market Positioning

Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States, granting it meaningful scale advantages and negotiating leverage with payors. Key competitive strengths include: - **Brand Reputation & Clinical Outcomes:** The company maintains consistently high clinical outcomes and patient satisfaction scores, supporting strong relationships with acute care referral sources. - **Geographic Diversification:** EHC operates a widespread network, reducing local market risk and supporting referral volume stability. - **Partnership Model:** Strategic joint ventures with large health systems expand market penetration and reinforce referral pipelines, creating network effects that smaller competitors find challenging to replicate. - **Expertise and Infrastructure:** Robust investment in clinical protocols, staff training, and data analytics supports operational efficiency and regulatory compliance.

🚀 Multi-Year Growth Drivers

A confluence of demographic, clinical, and structural factors underpin Encompass Health’s long-term growth potential: - **Aging Population:** The increasing number of elderly Americans drives sustained demand for post-acute and rehabilitative care, given the higher risk of stroke, orthopedic injury, and cardiac events with age. - **Shift to Value-Based Care:** Healthcare payors and systems increasingly favor providers demonstrating superior outcomes and lower rehospitalization rates, benefitting EHC given its focus on measurable results. - **Service Line Expansion:** Opportunities to expand into outpatient rehabilitation, home health, and adjacent post-acute services enable cross-selling and diversification. - **Network Expansion:** Continued investment in new hospital openings, de novo sites, and selective acquisitions supports addressable market growth while leveraging operational scale. - **Regulatory Tailwinds:** Policy emphasis on post-acute quality, increasing preference for inpatient rehabilitation over skilled nursing facilities (SNFs) for certain conditions, and potential for favorable payment reforms can further support growth.

⚠ Risk Factors to Monitor

While Encompass Health enjoys structural advantages, several key risks may affect its investment outlook: - **Reimbursement Pressure:** The company is highly exposed to government reimbursement rates and potential changes in Medicare and Medicaid policies. Adverse rate adjustments, changes in DRG coding, or payment reform could impact profitability. - **Regulatory Scrutiny:** Stringent federal and state regulations govern service quality, billing, and facility operations; compliance lapses may result in penalties or exclusion from federal programs. - **Labor Cost Inflation:** Nursing and allied health labor shortages are intensifying, potentially increasing wage pressures and affecting margin performance. - **Competition:** While less fragmented than other healthcare sub-sectors, competition from hospital systems, regional players, and emerging outpatient or home-based models remains a risk. - **Execution Risk:** New facility ramp-up, integration of acquisitions, and expansion into adjacent services require strong execution and cultural alignment.

📊 Valuation & Market View

Encompass Health is typically valued relative to its healthcare services peers, using forward multiples of EBITDA, earnings, or free cash flow. Premium valuations often reflect the company’s consistent cash generation, resilient reimbursement profile, and dominant market share within the inpatient rehabilitation sector. Market consensus generally recognizes Encompass Health as a defensive, secular growth play given its exposure to demographic megatrends and insulation from discretionary healthcare spending downturns. The capital structure, typically featuring a moderate leverage profile, supports steady dividends and opportunistic growth investments.

🔍 Investment Takeaway

Encompass Health offers exposure to structural healthcare growth trends via its dominant position in the U.S. inpatient rehabilitation market. Its revenue model, scale advantages, and reputation for quality care underpin sustainable cash flows and earnings resilience. Multi-year secular drivers—including an aging population, healthcare system value-based transformations, and regulatory support—provide a solid runway for disciplined expansion. Key risks stem from government reimbursement policies, labor market dynamics, and ongoing regulatory scrutiny. For investors seeking steady growth with defensive characteristics, Encompass Health represents a compelling opportunity within post-acute care services, supported by robust market positioning and long-term demand tailwinds.

⚠ AI-generated — informational only. Validate using filings before investing.

📢 Show latest earnings summary

EHC Q4 2025 Earnings Summary

Overall summary: Encompass Health delivered strong Q4 and full-year 2025 results with double-digit revenue and EBITDA growth, robust free cash flow, and lower premium labor costs. Capacity additions, superior quality metrics, and expanding referral channels (notably VA) support continued growth. Management is proactive on regulatory fronts (RCD, TEAM) and confident in mitigating selective Medicare Advantage headwinds through documentation, appeals, and payer engagement. 2026 guidance implies sustained top- and bottom-line growth, supported by a solid balance sheet and continued investment.

Growth

  • 2025 revenue +10.5% driven by 6% discharge growth and pricing/mix gains
  • 2025 adjusted EBITDA +14.9% on operating leverage and expense discipline
  • Q4 revenue +9.9% to ~$1.5B; discharges +5.3%; net revenue per discharge +4.1%
  • Premium labor spend down >$21M in 2025 vs. 2024; Q4 premium labor down $5.8M YoY
  • VA program: now 19% of managed care volume; Q4 discharges +~25%; FY +22%
  • Added 517 beds in 2025 (8 new hospitals/390 beds; 127 beds added to existing sites)

Business development

  • Opened 8 de novo hospitals in 2025; 4 contributed positive EBITDA in Q4
  • Planning small-format hospitals starting in 2027 to enable hub-and-spoke expansion
  • Migrated ERP to Oracle Fusion (cloud) with minimal disruption
  • Extended and expanded Palantir partnership to enhance documentation and denial management
  • Consolidated/closed two leased IRF units (Sewickley, PA; Cincinnati, OH)

Financials

  • Q4 adjusted EBITDA $335.6M (+15.9% YoY)
  • Q4 net revenue per discharge +4.1%, aided by a $2.7M payer settlement
  • Q4 bad debt 2.1% (flat YoY)
  • Q4 salary, wages & benefits per FTE +2.1%; benefits per FTE +2.9%
  • Q4 premium labor $23.8M (lowest since Q1’21); contract labor FTEs 1.1% of total
  • Reopening/ramp-up costs: $2.9M in Q4; $13.9M for FY 2025
  • Q4 adjusted free cash flow $235.4M (+23.6%); FY 2025 adjusted FCF $818M (+18.5%)

Capital & funding

  • 2025 capex $736M to support capacity additions and growth
  • Share repurchases $158M in 2025
  • Cash dividends >$70M in 2025
  • Net leverage 1.9x at year-end; long-term debt essentially flat YoY
  • Strong FCF supports continued investment and shareholder returns

Operations & strategy

  • RCD: Alabama hospitals’ cycle-4 affirmation ~93%; prepared for Texas/California expansion
  • Electing 100% prepayment review under RCD to reduce exposure to other Medicare audits
  • TEAM model effective Jan 1; 89 hospitals in initial markets (41 JV); no downside risk to acute partners in 2026 default track
  • Admit-and-appeal strategy for certain MA denials (up to ALJ/Federal court) to protect access
  • Ongoing AI/documentation enhancements (via Palantir) to improve admissions and denial responses
  • Strong quality outcomes: 2025 discharge to community 84.6%; to acute 8.6%; to SNF 6.1%

Market & outlook

  • Target demographic (IRF-eligible) growing ~4% annually; IRF bed supply gap widening
  • Large pool of IRF-appropriate patients still treated outside IRFs provides backfill opportunity
  • 2026 guidance: revenue $6.365B–$6.465B; adjusted EBITDA $1.34B–$1.38B; adjusted EPS $5.81–$6.10
  • Preparedness and historical resilience through prior episodic payment models (CJR, BPCI) underpin growth expectations
  • VA channel expansion and fee-for-service Medicare strength expected to offset selective MA headwinds

Risks & headwinds

  • Regulatory uncertainty: RCD expansion and TEAM model implementation
  • Medicare Advantage constraints: one national payer’s notably lower conversion rate; two major payers <20% conversion in some markets
  • Near-term volume headwinds from unit closures/consolidations (Q3 impact ~30 bps; Q4 ~45 bps)
  • Cost pressures in benefits (+2.9% per FTE) despite easing premium labor
  • Timing risks around Medicare certifications and start-up ramps for new hospitals

Sentiment: positive

📊 Encompass Health Corporation (EHC) — AI Scoring Summary

📊 AI Stock Rating — Summary

For the quarter ending December 31, 2025, EHC reported revenue of $1.54 billion and net income of $146.1 million, resulting in an EPS of $1.46. Net margin stands at approximately 9.5%. Notably, EHC's operating cash flow was negative at -$561.3 million, leading to a free cash flow of -$748.4 million. Year-over-year revenue growth details are not disclosed here. Revenue growth appears stable given the strong quarterly revenue figure. However, profitability is under pressure with significant cash outflows impacting free cash flow. Despite these pressures, the company maintains a robust equity base of $3.28 billion against total liabilities of $3.81 billion, yielding a net debt of $194.5 million, indicating sound financial health. The ongoing distribution of dividends and stock repurchases reflect commitment to shareholder returns, although negative FCF poses a risk in the longer term. The analyst consensus price target ranges from $140 to $153, suggesting cautious optimism on valuation. Overall, the financial resilience and commitment to returns offset concerns about cash flow challenges.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenue stability is shown with consistent figures. More clarity on growth drivers is needed.

Profitability — Score: 5/10

EPS and net margin at a stable level, but free cash flow issues affect overall profit quality.

Cash Flow Quality — Score: 3/10

Negative operating and free cash flow raise concerns over short-term financial management.

Leverage & Balance Sheet — Score: 7/10

Strong total equity with manageable net debt indicates financial stability.

Shareholder Returns — Score: 6/10

Sustained dividends and repurchases support shareholder value, but FCF constraints could threaten future distributions.

Analyst Sentiment & Valuation — Score: 5/10

Analyst target prices show moderate optimism; valuation depends on addressing cash flow issues.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

BAX logo

BAXTER INTERNATIONAL INC (BAX)

Healthcare

$10.48B

DVA logo

DAVITA INC (DVA)

Healthcare

$10.45B

QGEN logo

QIAGEN NV (QGEN)

Healthcare

$10.26B

RVTY logo

REVVITY INC (RVTY)

Healthcare

$11.41B

HSIC logo

HENRY SCHEIN INC (HSIC)

Healthcare

$9.99B

JAZZ logo

JAZZ PHARMACEUTICALS PLC (JAZZ)

Healthcare

$11.55B